Premium
Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft‐versus‐host reaction
Author(s) -
Joo SunYoung,
Cho KyungAh,
Jung YunJae,
Kim Hanseong,
Park SeongYeol,
Choi YongBock,
Hong Kyungman,
Woo SoYoun,
Seoh JuYoung,
Ryu KyungHa
Publication year - 2011
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1042/cbi20100563
Subject(s) - mesenchymal stem cell , in vivo , splenocyte , bone marrow , transplantation , green fluorescent protein , stem cell , cancer research , immunology , graft versus host disease , medicine , pathology , biology , immune system , microbiology and biotechnology , surgery , biochemistry , gene
Cell therapy using MSCs (mesenchymal stem cells) might be effective treatment for refractory GVHD (graft‐versus‐host disease). However, the fate and distribution of MSCs after transplantation remains unclear. In this study, an animal model was developed to monitor the dynamic distribution of MSCs in mice with GVHD. A GVHD mouse model was established by transplanting C57BL/6 donor bone marrow cells and C57BL/6 EGFP (enhanced green fluorescent protein) splenocytes into lethally irradiated BALB/c nude recipient mice. Donor MSCs were obtained from MHC‐identical C57BL/6 RFP (red fluorescent protein) mice and infused into the recipient mice on the same transplantation day. In vivo movement of the donor splenocytes (EGFP) and MSCs (RFP) were evaluated by measuring the biofluorescence (IVIS—Xenogen system). Donor splenocytes and MSCs reached the lungs first, and then the gastrointestinal tract, lymph nodes and skin, in that order; the transit time and localization site of these cells were very similar. In the recipient mouse with GVHD, the number of detectable cells declined with time, as assessed by biofluorescence imaging and confirmed by RT (real‐time)‐PCR. This bioimaging system might be useful for preclinical testing and the design of therapeutic strategies for monitoring the dynamic distribution of MSCs with GVHD.